Injectable natural progesterone: a physiologic alternative following the withdrawal of 17α-hydroxyprogesterone caproate for preterm birth prevention
DOI:
https://doi.org/10.18203/2320-1770.ijrcog20260348Keywords:
Preterm birth, Natural progesterone, 17-OHPC, Intramuscular progesterone, Pregnancy maintenance, ProgestogensAbstract
Following the withdrawal of 17-alpha hydroxyprogesterone caproate (17-OHPC; formerly marketed as MAKENA) there is a therapeutic gap in the prevention of recurrent spontaneous preterm birth (PTB) in women with singleton pregnancies and a history of prior PTB. Originally granted accelerated approval based on the Meis trial, 17-OHPC failed to demonstrate clinical benefit in the confirmatory PROLONG trial and raised long-term safety concerns regarding childhood cancer risk. In contrast, natural progesterone, an endogenous hormone essential for pregnancy maintenance, can provide strong biological plausibility for myometrial quiescence through evident genomic and non-genomic mechanisms. Although no head-to-head trials exist comparing intramuscular (IM) natural progesterone with 17-OHPC for PTB, physiological reasoning, pharmacokinetic advantages of the native molecule, and indirect evidence from historical and contemporary progestogen studies support its consideration as a viable alternative. In this short communication we highlight the mechanistic rationale for IM natural progesterone while acknowledging the need for dedicated clinical trials to establish efficacy and optimal dosing in modern obstetric practice.
References
Cao G, Liu J, Liu M. Global, regional, and national incidence and mortality of neonatal preterm birth, 1990–2019. JAMA Pediatr. 2022;176(8):787-96. DOI: https://doi.org/10.1001/jamapediatrics.2022.1622
Mesiano SA, Peters GA, Amini P, Wilson RA, Tochtrop GP, van den Akker F. Progestin therapy to prevent preterm birth: history and effectiveness of current strategies and development of novel approaches. Placenta. 2019;79:46-52. DOI: https://doi.org/10.1016/j.placenta.2019.01.018
Norwitz ER, Norwitz GA, Diaz AM, Davis J. Anatomy of an FDA drug recall: the 17α-hydroxyprogesterone accelerated approval and withdrawal processes. Curr Obstet Gynecol Rep. 2024;13(3):171-9. DOI: https://doi.org/10.1007/s13669-024-00401-1
Meis PJ, Klebanoff M, Thom E, Dombrowski MP, Sibai B, Moawad AH, et al. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med. 2003;348(24):2379-85. DOI: https://doi.org/10.1056/NEJMoa035140
Blackwell SC, Gyamfi-Bannerman C, Biggio JR Jr, Chauhan SP, Hughes BL, Louis JM, et al. 17-OHPC to prevent recurrent preterm birth in singleton gestations (PROLONG study): a multicenter, international, randomized double-blind trial. Am J Perinatol. 2020;37(2):127-36. DOI: https://doi.org/10.1055/s-0039-3400227
Murphy CC, Cirillo PM, Krigbaum NY, Cohn BA. In utero exposure to 17α-hydroxyprogesterone caproate and risk of cancer in offspring. Am J Obstet Gynecol. 2022;226(1):132.e1-14. DOI: https://doi.org/10.1016/j.ajog.2021.10.035
American College of Obstetricians and Gynecologists (ACOG). Updated clinical guidance for the use of progestogen supplementation for the prevention of recurrent preterm birth. Washington (DC): ACOG; 2025. Available at: https://www.acog.org. Accessed on 06 November 2025.
Romero R, Conde-Agudelo A, El-Refaie W, Rode L, Brizot ML, Cetingoz E, et al. Vaginal progesterone decreases preterm birth and neonatal morbidity and mortality in women with a twin gestation and a short cervix: an updated meta-analysis of individual patient data. Ultrasound Obstet Gynecol. 2017;49(3):303-14. DOI: https://doi.org/10.1002/uog.17397
Hassan SS, Romero R, Vidyadhari D, Fusey S, Baxter JK, Khandelwal M, et al. Vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix: a multicenter, randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol. 2011;38(1):18-31. DOI: https://doi.org/10.1002/uog.9017
Romero R, Stanczyk FZ. Progesterone is not the same as 17α-hydroxyprogesterone caproate: implications for obstetrical practice. Am J Obstet Gynecol. 2013;208(6):421-6. DOI: https://doi.org/10.1016/j.ajog.2013.04.027
Pieber D, Allport VC, Hills F, Johnson M, Bennett PR. Interactions between progesterone receptor isoforms in myometrial cells in human labour. Mol Hum Reprod. 2001;7(9):875-9. DOI: https://doi.org/10.1093/molehr/7.9.875
Biggio JR Jr. Current approaches to risk assessment and prevention of preterm birth—a continuing public health crisis. Ochsner J. 2020;20(4):426-33. DOI: https://doi.org/10.31486/toj.20.0005
Phillips C, Velji Z, Hanly C, Metcalfe A. Risk of recurrent spontaneous preterm birth: a systematic review and meta-analysis. BMJ Open. 2017;7(6):e015402. DOI: https://doi.org/10.1136/bmjopen-2016-015402
Romero R, Conde-Agudelo A, Da Fonseca E, O’Brien JM, Cetingoz E, Creasy GW, et al. Vaginal progesterone for preventing preterm birth and adverse perinatal outcomes in singleton gestations with a short cervix: a meta-analysis of individual patient data. Am J Obstet Gynecol. 2018;218(2):161-80. DOI: https://doi.org/10.1016/j.ajog.2017.11.576
March of Dimes. Prematurity profile—United States. Arlington (VA): March of Dimes. 2026. Available at: https://www.marchofdimes.org. Accessed on 06 November 2025.
Shennan A, Suff N, Leigh Simpson J, Jacobsson B, Mol BW, Grobman WA. FIGO good practice recommendations on progestogens for prevention of preterm delivery. Int J Gynaecol Obstet. 2021;155(1):16-8. DOI: https://doi.org/10.1002/ijgo.13852
Manuck TA, Gyamfi-Bannerman C, Saade G. What now? A critical evaluation of over 20 years of clinical and research experience with 17-alpha hydroxyprogesterone caproate for recurrent preterm birth prevention. Am J Obstet Gynecol MFM. 2023;5(10):101108. DOI: https://doi.org/10.1016/j.ajogmf.2023.101108
Futterman ID, Gilroy L, Zayat N, Balhotra K, Weedon J, Minkoff H. Changes in use of 17-OHPC after the PROLONG trial: a physician survey. J Perinat Med. 2023;51(8):1013-8. DOI: https://doi.org/10.1515/jpm-2023-0085
Gallagher JR, Gudeman J, Heap K, Vink J, Carroll S. Understanding if, how, and why women with prior spontaneous preterm births are treated with progestogens: a national survey of obstetrician practice patterns. AJP Rep. 2018;8(4):e315-24. DOI: https://doi.org/10.1055/s-0038-1675556
Beam AL, Fried I, Palmer N, Agniel D, Brat G, Fox K, et al. Estimates of healthcare spending for preterm and low-birthweight infants in a commercially insured population: 2008–2016. J Perinatol. 2020;40(7):1091-9. DOI: https://doi.org/10.1038/s41372-020-0635-z
Mendelson CR, Gao L, Montalbano AP. Multifactorial regulation of myometrial contractility during pregnancy and parturition. Front Endocrinol (Lausanne). 2019;10:714. DOI: https://doi.org/10.3389/fendo.2019.00714
Tan H, Yi L, Rote NS, Hurd WW, Mesiano S. Progesterone receptor-A and -B have opposite effects on proinflammatory gene expression in human myometrial cells. J Clin Endocrinol Metab. 2012;97(5):E719-30. DOI: https://doi.org/10.1210/jc.2011-3251
Mesiano S. Myometrial progesterone responsiveness and the control of human parturition. J Soc Gynecol Investig. 2004;11(4):193-202. DOI: https://doi.org/10.1016/j.jsgi.2003.12.004
Scarpin KM, Graham JD, Mote PA, Clarke CL. Progesterone action in human tissues: regulation by progesterone receptor isoform expression, nuclear positioning and coregulator expression. Nucl Recept Signal. 2009;7:e009. DOI: https://doi.org/10.1621/nrs.07009
Enfield K, Avenant C, Hapgood JP. Progestogens exhibit progestogen-, promoter- and isoform-specific effects via the progesterone receptor. Steroids. 2022;187:109094. DOI: https://doi.org/10.1016/j.steroids.2022.109094
Green ES, Arck PC. Pathogenesis of preterm birth: bidirectional inflammation in mother and fetus. Semin Immunopathol. 2020;42(4):413-29. DOI: https://doi.org/10.1007/s00281-020-00807-y
Romero R, Espinoza J, Gonçalves LF, Kusanovic JP, Friel LA, Nien JK. Inflammation in preterm and term labour and delivery. Semin Fetal Neonatal Med. 2006;11(5):317-26. DOI: https://doi.org/10.1016/j.siny.2006.05.001
Mehta S, Chaturvedi A. Comparison of the pharmacokinetics, bioequivalence and safety of aqueous progesterone administered intramuscularly or subcutaneously versus oil-based intramuscular progesterone. J Clin Diagn Res. 2023;17(5). DOI: https://doi.org/10.7860/JCDR/2023/56291.17889
Nelson DB, Herrera CL, McIntire DD, Cunningham FG. The end is where we start from: withdrawal of 17-alpha hydroxyprogesterone caproate to prevent recurrent preterm birth. Am J Obstet Gynecol. 2024;230(1):1-9. DOI: https://doi.org/10.1016/j.ajog.2023.08.031
Nold C, Maubert M, Anton L, Yellon S, Elovitz MA. Prevention of preterm birth by progestational agents: what are the molecular mechanisms? Am J Obstet Gynecol. 2013;208(3):223.e1-7. DOI: https://doi.org/10.1016/j.ajog.2013.01.020
Nelson DB, Fomina YY. Challenges in using progestin to prevent singleton preterm births: current knowledge and clinical advice. Int J Womens Health. 2024;16:119-30. DOI: https://doi.org/10.2147/IJWH.S394305
Allahbadia GN. Has ART finally got a patient-friendly progesterone? J Obstet Gynaecol India. 2015;65(5):289-92. DOI: https://doi.org/10.1007/s13224-015-0731-8
Brenner WE, Hendricks CH. Effect of medroxyprogesterone acetate upon the duration and characteristics of human gestation and labor. Am J Obstet Gynecol. 1962;83(8):1094-8. DOI: https://doi.org/10.1016/S0002-9378(16)35945-2
Jarde A, Lutsiv O, Beyene J, McDonald SD. Vaginal progesterone, oral progesterone, 17-OHPC, cerclage, and pessary for preventing preterm birth in at-risk singleton pregnancies: an updated systematic review and network meta-analysis. BJOG. 2019;126(5):556-67. DOI: https://doi.org/10.1111/1471-0528.15566
Bomba-Opon DA, Kosinska-Kaczynska K, Kosinski P, Wegrzyn P, Kaczynski B, Wielgos M. Vaginal progesterone after tocolytic therapy in threatened preterm labor. J Matern Fetal Neonatal Med. 2012;25(7):1156-9. DOI: https://doi.org/10.3109/14767058.2011.629014
Yadav G, Gupta S, Singh P, Kansara M, Kathuria P, Gothwal M, et al. The role of vaginal progesterone in established pre-term labor: a randomized controlled trial. J Fam Med Prim Care. 2022;11(11):7042-7. DOI: https://doi.org/10.4103/jfmpc.jfmpc_884_22
Hyett J, Asadi N, Zare Khafri M, Vafaei H, Kasraeian M, Salehi A, et al. Vaginal progesterone as maintenance therapy in women with arrested preterm labor. J Matern Fetal Neonatal Med. 2022;35(6):1134-40. DOI: https://doi.org/10.1080/14767058.2020.1743662
Suhag A, Saccone G, Berghella V. Vaginal progesterone for maintenance tocolysis: a systematic review and meta-analysis of randomized trials. Am J Obstet Gynecol. 2015;213(4):479-87. DOI: https://doi.org/10.1016/j.ajog.2015.03.031
Ferrari F, Minozzi S, Basile L, Chiossi G, Facchinetti F. Progestogens for maintenance tocolysis in symptomatic women: a systematic review and meta-analysis. PLoS One. 2023;18(2):e0277563. DOI: https://doi.org/10.1371/journal.pone.0277563
Beltsos AN, Sanchez MD, Doody KJ, Bush MR, Domar AD, Collins MG. Patients’ administration preferences: progesterone vaginal insert compared to intramuscular progesterone for luteal phase support. Reprod Health. 2014;11:78. DOI: https://doi.org/10.1186/1742-4755-11-78
Romero R, Yeo L, Miranda J, Hassan SS, Conde-Agudelo A, Chaiworapongsa T. A blueprint for the prevention of preterm birth: vaginal progesterone in women with a short cervix. J Perinat Med. 2013;41(1):27-44. DOI: https://doi.org/10.1515/jpm-2012-0272
Zhao Y, D’Souza R, Gao Y, Hao Q, Kallas-Silva L, Steen JP, et al. Progestogens in women with threatened miscarriage or recurrent miscarriage: a meta-analysis. Acta Obstet Gynecol Scand. 2024;103(9):1689-701. DOI: https://doi.org/10.1111/aogs.14829
Wagh GN, Kundavi Shankar KM, Bachani S. A review of conventional and sustained-release formulations of oral natural micronized progesterone in obstetric indications. Drugs Context. 2021;10. DOI: https://doi.org/10.7573/dic.2021-7-1
Alsulmi ES, Alfaraj M, Faden Y, Al Qahtani N. The use of progesterone during pregnancy to prevent preterm birth. Saudi Med J. 2020;41(4):333-40. DOI: https://doi.org/10.15537/smj.2020.4.25036
Jacobsson B, Simpson JL. FIGO good practice recommendations for reducing preterm birth and improving child outcomes. Int J Gynaecol Obstet. 2021;155(1):1-4. DOI: https://doi.org/10.1002/ijgo.13863
Norman JE. Progesterone and preterm birth. Int J Gynaecol Obstet. 2020;150(1):24-30. DOI: https://doi.org/10.1002/ijgo.13187
Downloads
Published
How to Cite
Issue
Section
